ChronoScale vs Taylor Devices
CHRN and TAYD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CHRN | TAYD |
|---|---|---|
| Size and price | ||
| Market cap | – | $188M |
| Share price | $9.95 | $58.14 |
| Change, 1 year | 82.6% | 33.3% |
| Change, 5 years | −80.5% | 406% |
| Beta (5Y) | 1.27 | 0.59 |
| Employees | – | 135 |
| StockData Score | ||
| Total score | – | 12 |
| Valuation score | – | 1 |
| Growth score | – | 1 |
| Performance score | – | 4 |
| Health score | – | 6 |
| Dividend score | – | 0 |
| Valuation | ||
| P/S | – | 4.8× |
| P/B | – | 2.6× |
| EV/EBITDA | – | 27.0× |
| P/FCF | – | 15.5× |
| FCF yield | – | 6.5% |
| Fair value | – | $39.50 |
| Margin of safety | – | −47.2% |
| Growth | ||
| Revenue growth (TTM) | – | −12.5% |
| Revenue growth, 5Y average | – | 13.1% |
| Net income growth (TTM) | – | −23.6% |
| EPS growth, 5Y average | – | 54.3% |
| Profitability | ||
| Gross margin | – | 41.2% |
| Operating margin | – | 13.2% |
| Net margin | – | 17.5% |
| FCF margin | – | 31.1% |
| Return on equity | – | 9.9% |
| Return on invested capital | – | 19.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | – | 8.66 |
| Altman Z-score | – | 17.53 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −1.0% |
| Shareholder yield | – | −1.0% |
| Ownership | ||
| Held by institutions | 0.73% | 46.3% |
| Held by insiders | 100% | 2.5% |
| Insider net buying, 12 months | $1.2M (better) | −$897K |
| Short interest, % of float | – | 4.0% |
Go deeper
- CHRN stock overview
- CHRN income statement
- CHRN valuation and score
- TAYD stock overview
- TAYD income statement
- TAYD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.